Get the Stockscreener App
3.685
0.68%
0.025
After Hours:
3.70
0.015
+0.41%
Akebia Therapeutics Inc stock is traded at $3.685, with a volume of 2.45M.
It is up +0.68% in the last 24 hours and up +1.24% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$3.66
Open:
$3.66
24h Volume:
2.45M
Relative Volume:
0.52
Market Cap:
$967.81M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-13.16
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
-4.04%
1M Performance:
+1.24%
6M Performance:
+64.51%
1Y Performance:
+167.03%
1-Day Range:
$3.62
$3.7379
1-Week Range:
$3.47
$3.85
52-Week Range:
$1.07
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
3.685 | 961.25M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
145.79 | 66.25B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.72 | 42.95B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.43 | 43.30B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.45 | 19.30B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
128.23 | 13.53B | 2.41B | 305.80M | 492.20M | 2.95 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-04-25 | Resumed | H.C. Wainwright | Buy |
| Apr-28-25 | Initiated | Leerink Partners | Outperform |
| Apr-01-25 | Initiated | Jefferies | Buy |
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
When is Akebia Therapeutics Inc. stock expected to show significant growthTop Growth Trend Scanner With High Returns - jammulinksnews.com
Would Akebia Therapeutics (NASDAQ:AKBA) Be Better Off With Less Debt? - 富途牛牛
Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Forecast Opportunities For Beginners - jammulinksnews.com
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights - The Manila Times
What are analysts’ price targets for Akebia Therapeutics Inc. in the next 12 monthsValue Investing Tracker To Watch Now - jammulinksnews.com
How to monitor Akebia Therapeutics Inc. with trend dashboardsEarnings Play Trade Plan With Alerts Shared - metal.it
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Move—What’s Really Behind the Surge? - AInvest
Why Akebia Therapeutics Inc. stock attracts strong analyst attentionLow Risk Stock Strategies - beatles.ru
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Spike — But No Clear Fundamental Trigger - AInvest
Akebia Therapeutics (AKBA.O) Sees Sharp Intraday Move – But No Fundamental Catalyst - AInvest
Akebia Therapeutics Inc. Moves Into Overbought Range Analysts CautiousTriple Digit Growth Focused Trade Plan Reviewed - metal.it
Trading Bots Trigger Alerts on Akebia Therapeutics Inc. ActivityTriple Digit Return Stock Predictions Released - metal.it
Applying big data sentiment scoring on Akebia Therapeutics Inc.Entry Alert With Low Drawdown Strategy Noted - metal.it
Published on: 2025-07-28 05:33:13 - jammulinksnews.com
How does Akebia Therapeutics Inc. generate profit in a changing economyFree Stock Index Interpretation - jammulinksnews.com
What is the dividend policy of Akebia Therapeutics Inc. stockNavigate market shifts with confidence - jammulinksnews.com
Is Akebia Therapeutics Inc. a growth stock or a value stockAchieve exceptional returns with expert guidance - jammulinksnews.com
What makes Akebia Therapeutics Inc. stock price move sharplyDiscover stocks with explosive upside potential - jammulinksnews.com
How many analysts rate Akebia Therapeutics Inc. as a “Buy”Discover stocks with superior performance - jammulinksnews.com
Is it the right time to buy Akebia Therapeutics Inc. stockRecord-setting profit potential - jammulinksnews.com
Akebia Rides Vafseo Launch To A Strong Year - Finimize
How Interest Rate Changes Impact Akebia Therapeutics Inc. Stock PerformanceDefensive Stock Picks with Upside - metal.it
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share - MSN
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy - Insider Monkey
What drives Akebia Therapeutics Inc. stock priceFree Capital Allocation Plans - PrintWeekIndia
How Akebia Therapeutics Inc. stock reacts to Fed policy changesRapidly growing investment returns - jammulinksnews.com
Is Akebia Therapeutics Inc. a good long term investmentConsistent high-yield stocks - Autocar Professional
Is Akebia Therapeutics Inc. stock overhyped or has real potentialHigh-yield growth strategies - jammulinksnews.com
What analysts say about Akebia Therapeutics Inc. stockFree Consultation - Autocar Professional
Akebia Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - jammulinksnews.com
Lobbying Update: $460,000 of AKEBIA THERAPEUTICS INC. lobbying was just disclosed - Nasdaq
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.90%
0.85%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):